Bioversys Ag

Bioversys Ag company information, Employees & Contact Information

Explore related pages

Related company profiles:

BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready), and tuberculosis (Alpibectir, Phase 2) in collaboration with GSK and a consortium from the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.

Company Details

Employees
29
Founded
-
Address
Hochbergerstrasse 60c, Technologiepark,switzerland
Phone
+41 78 670 40 85
Email
in****@****sys.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Basel
Looking for a particular Bioversys Ag employee's phone or email?

Bioversys Ag Questions

News

Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025 - Yahoo Finance

Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025 Yahoo Finance

BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024 - GlobeNewswire

BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024 GlobeNewswire

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets FirstWord Pharma

BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development The Pharma Letter

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics pharmaphorum

Swiss biopharma firm BioVersys plans IPO in first quarter - Reuters

Swiss biopharma firm BioVersys plans IPO in first quarter Reuters

Is BioVersys (VTX:BIOV) A Risky Investment? - simplywall.st

Is BioVersys (VTX:BIOV) A Risky Investment? simplywall.st

BioVersys sets IPO price at CHF 36.00 per share ahead of SIX Swiss Exchange debut - Venturelab Swiss

BioVersys sets IPO price at CHF 36.00 per share ahead of SIX Swiss Exchange debut Venturelab Swiss

AMR biotech BioVersys plans to float on Swiss stock exchange - pharmaphorum

AMR biotech BioVersys plans to float on Swiss stock exchange pharmaphorum

BioVersys receives EMA orphan designation for the combination of alpibectir and ethionamide for the treatment of TB - European AIDS Treatment Group

BioVersys receives EMA orphan designation for the combination of alpibectir and ethionamide for the treatment of TB European AIDS Treatment Group

Latham Advises on BioVersys’ CHF 213 Million IPO - Latham & Watkins LLP

Latham Advises on BioVersys’ CHF 213 Million IPO Latham & Watkins LLP

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program Fierce Biotech

Swiss biotech firm BioVersys plans IPO at SIX Swiss Exchange in first quarter 2025 - Venturelab Swiss

Swiss biotech firm BioVersys plans IPO at SIX Swiss Exchange in first quarter 2025 Venturelab Swiss

BioVersys AG Reports Key Financials and Clinical Progress for H1 2025 - TipRanks

BioVersys AG Reports Key Financials and Clinical Progress for H1 2025 TipRanks

Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch

Swiss firm BioVersys signs deal with Shionogi for antibiotics research SWI swissinfo.ch

BioVersys: saving lives in resistant times - Nature

BioVersys: saving lives in resistant times Nature

BioVersys, GSK Expand Strategic TB Collaboration - Contract Pharma

BioVersys, GSK Expand Strategic TB Collaboration Contract Pharma

From Lab Bench to Bell Ring – Marc Gitzinger on BioVersys' road to IPO - Venturelab Swiss

From Lab Bench to Bell Ring – Marc Gitzinger on BioVersys' road to IPO Venturelab Swiss

Is BioVersys AG (W33) stock undervalued after correction - July 2025 Technicals & Free Weekly Watchlist of Top Performers - Trung tâm Dự báo KTTV quốc gia

Is BioVersys AG (W33) stock undervalued after correction - July 2025 Technicals & Free Weekly Watchlist of Top Performers Trung tâm Dự báo KTTV quốc gia

Will BioVersys AG (W33) stock gain from lower interest rates - Stock Surge & Accurate Trade Setup Notifications - Trung tâm Dự báo KTTV quốc gia

Will BioVersys AG (W33) stock gain from lower interest rates - Stock Surge & Accurate Trade Setup Notifications Trung tâm Dự báo KTTV quốc gia

Biotech company BioVersys is first Swiss IPO of 2025 - SWI swissinfo.ch

Biotech company BioVersys is first Swiss IPO of 2025 SWI swissinfo.ch

GSK and Bioversys advance ethionamide boosters for treating tuberculosis - BioWorld MedTech

GSK and Bioversys advance ethionamide boosters for treating tuberculosis BioWorld MedTech

BioVersys receives up to €8m from CARB-X - European Biotechnology Magazine

BioVersys receives up to €8m from CARB-X European Biotechnology Magazine

Top Bioversys Ag Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant